Natixis Advisors LLC Has $3.92 Million Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Key Points

• Natixis Advisors LLC increased its stake in Smith & Nephew by 9.7%, acquiring an additional 12,197 shares, bringing its total holdings to 137,986 shares valued at approximately $3.9 million.
• Several institutional investors, including Hexagon Capital Partners LLC and Bessemer Group Inc., made significant increases to their shares in Smith & Nephew during the first quarter, highlighting enhanced investor interest.
• Smith & Nephew's stock rating was recently downgraded by HSBC from "buy" to "hold", with the current consensus rating also being "hold" at a price target of $28.00.

Natixis Advisors LLC lifted its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 9.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 137,986 shares of the medical equipment provider's stock after purchasing an additional 12,197 shares during the period. Natixis Advisors LLC's holdings in Smith & Nephew SNATS were worth $3,915,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SNN. J. Goldman & Co LP acquired a new position in Smith & Nephew SNATS in the fourth quarter valued at about $47,700,000. Causeway Capital Management LLC bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at approximately $11,820,000. Northern Trust Corp increased its stake in Smith & Nephew SNATS by 169.9% in the fourth quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider's stock valued at $12,496,000 after purchasing an additional 320,054 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at approximately $6,132,000. Finally, Raymond James Financial Inc. bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at approximately $4,992,000. Institutional investors own 25.64% of the company's stock.

Analyst Upgrades and Downgrades

SNN has been the subject of a number of recent analyst reports. Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group increased their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Finally, HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $28.00.

Smith & Nephew SNATS Price Performance

SNN stock traded up $0.03 during mid-day trading on Friday, hitting $36.11. The stock had a trading volume of 1,334,815 shares, compared to its average volume of 1,071,249. The company has a current ratio of 3.00, a quick ratio of 1.33 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $36.56. The firm has a market capitalization of $15.82 billion, a P/E ratio of 16.72, a P/E/G ratio of 1.10 and a beta of 0.68. The firm has a fifty day simple moving average of $30.57 and a 200 day simple moving average of $28.46.

Smith & Nephew SNATS Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be issued a dividend of $0.285 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's payout ratio is 41.20%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.